Pelthos Therapeutics (PTHS) Net Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly Net Margin of 131.29% for Q4 2025, up 97.62% quarter-over-quarter from 5523.13% in Q3 2025.

Pelthos Therapeutics (PTHS) Net Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' Net Margin history runs 1 years deep, the most recent figure standing at 131.29% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	30.23%
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	31.16%
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	-16.51%
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	12.09%
10	Pelthos Therapeutics	93.05 Mn	68.49 Mn	21.23 Mn	-182.92%

Download Data